Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028 Report highlights:
Global LAG-3 Inhibitor Market, Drug Sales, Price & Clinical Trials Insight 2028 Report highlights:
- Global LAG-3 Inhibitor Drug Market Opportunity Assessment
- Number Of LAG-3 Inhibitor Drugs In Market: 1 Drug
- Approved LAG-3 Inhibitor Drug Dosage, Patent & Pricing Insight
- Number Of LAG-3 Inhibitor Drugs In Clinical Trials: > 35 Drugs
- LAG-3 Inhibitor Drugs Clinical Trials Insight By Company, Country, Indication, & Phase
- LAG-3 Targeted Therapy Approaches
- Completive Landscape: Company Financials & Anti LAG-3 Antibodies in Trials
Download Report:
https://www.kuickresearch.com/report-lag3-lag-3-inhibitor-anti-lag3-lag-3-antibody-antibodies
Immunotherapy has transformed the treatment landscape of cancer and immune checkpoint inhibitors have been leading this revolutionary path for quite some time. After nearly a decade of PDl-1 and CTLA-4 targeting therapies dominating the market, the field of cancer immunotherapy is branching out. With the industry constantly looking for newer approaches, the progress in genetic analysis has made the identification of other immune checkpoint inhibitors much easier. The discovery of LAG3 receptor and approval of LAG3 inhibitor drug has been a major topic of discussion among the industry players.
On March 2022, the US FDA approved the first ever LAG-3 blocking antibody combination, Opdualag as a treatment for patients with unresectable or metastatic melanoma. The drug is a first-in-class, fixed dose dual immunotherapy combination treatment with PD-1 inhibitor Nivolumab and novel LAG-3 blocking antibody Relatimab. The approval is based on the randomized phase II/III study; RELATIVITY-047 which demonstrated doubled the median progression free survival time for patients.
The approval of the drug introduced a new checkpoint immunotherapy target to the cancer treatment arsenal and the approval of Odualag developed by Bristol Myers Squibb is particularly significant as it introduces an entirely new combination of two immunotherapies that may act together to help improve anti-tumor response. After the therapeutic approach gained the market’s interest, Immutep, another leading biotechnology company that focuses on developing cancer immunotherapy treatments is keen to enter the LAG-3 inhibitor market.
Recently, by the end of 2022, Eftilagimod alpha (Efti), a LAG-3 checkpoint inhibitor was granted its fast track designation for its use in combination with Pembrolizumab as a frontline treatment for patients with stage IIIb/IV non-small cell lung cancer. The drug developed by Immutep, is a first-in-class antigen presenting cell activator and the study showed that the combination of Efti with Merck’s anti PD-1 antibody has potential to provide a safer and better tolerated alternative.
Currently, the pipeline of LAG-3 targeted therapies is slowly filling with many companies focusing their research into developing novel approaches to treat tumors by targeting LAG-3 receptor. For instance, Regeneron Pharmaceuticals have presented positive data from multiple expansion cohorts of an initial phase I trial for an investigational combination of LAG-3 inhibitor drug, Fianlimab and PD-1 inhibitor Libtayo in advanced melanoma. Although the potential use of both the drugs in combination is investigational and safety and efficacy of this combination has not been evaluated by any regulatory authority.
The increasing burden of cancer all over the world is pushing the pharmaceutical stakeholders to develop further novel therapeutics for it and the adoption of LAG-3 inhibitors overall suggests that the market is surely to expand in the future. Some of the key payers that are actively working towards developing LAG-3 targeted therapies include; Macrogenics, Zai Lab, Bristol Myers Squibb, Ono Pharmaceuticals and several others.
Looking at the significant impact that Odualag had on the industry as a LAG-3 inhibitor, it is foreseeable that the future of LAG-3 targeted therapies will be thriving. Numerous clinical trials ongoing which are constantly evaluating the role of LAG-3 inhibitors not only as a cancer immunotherapy but also in other diseases like diabetes, multiple sclerosis, Parkinson and other immune disorders. This report aims to provide a detailed knowledge on targeted therapies which have been approved or are under trials. Additionally, the report also highlights various market opportunities that are available or might be available in the future of LAG-3 market. There are several factors that drive the markets growth or challenge its development; this report also provides insights on such factors.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com